Surgery Partners (SGRY) 주식 개요
는 자회사와 함께 미국에서 수술 시설 및 보조 서비스 네트워크를 소유하고 운영합니다. 자세히 보기
강점
위험 분석
우리의 위험 점검에서 SGRY에 대한 위험이 감지되지 않았습니다.
SGRY Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Surgery Partners, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$17.00 |
| 52주 최고가 | US$24.10 |
| 52주 최저가 | US$11.41 |
| 베타 | 1.89 |
| 1개월 변동 | 24.00% |
| 3개월 변동 | 34.49% |
| 1년 변동 | -22.83% |
| 3년 변동 | -60.87% |
| 5년 변동 | -73.06% |
| IPO 이후 변동 | -7.76% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 30
SGRY: Q1 Execution And 2026 Outlook Will Support Margin Recovery
Analysts have revised their fair value estimate for Surgery Partners from $25.00 to about $23.49, citing updated assessments of discount rates, revenue growth, profit margins, and future P/E assumptions based on recent research. Analyst Commentary Recent Street research around Surgery Partners highlights a mix of adjustments to price targets, with some bullish analysts focusing on the company’s capacity to execute on its plans while reassessing risk and return assumptions.분석 기사 • Jun 19
Surgery Partners (SGRY) Stock Could Be 19% Undervalued As Growth And Debt Concerns Build
Recent commentary on Surgery Partners (SGRY) has focused on slowing sales volume growth, softer revenue growth expectations, and ongoing high debt levels. This combination appears to be affecting sentiment toward the stock. See our latest analysis for Surgery Partners. At a share price of $14.55, Surgery Partners has seen a 30 day share price return of 7.86% and a 90 day share price return of 23.31%. However, the 1 year total shareholder return is down 24.61%, pointing to some recent momentum...
내러티브 업데이트 • Jun 15
SGRY: Reset Expectations And Steady Guidance Will Shape Future Multiple Potential
Analysts cut the fair value estimate for Surgery Partners stock by $4 to $14, reflecting updated assumptions around revenue growth, profit margins, the discount rate, and a lower future P/E multiple, despite recent mixed price target moves at Jefferies. Analyst Commentary Recent research shows mixed views on Surgery Partners, with some analysts adjusting price targets in both directions over a short period.
내러티브 업데이트 • Jun 01
SGRY: Margin Repair And Payer Mix Reset Will Support 2026 EBITDA Recovery
The analyst-derived fair value estimate for Surgery Partners has shifted from about $18.80 to roughly $17.95, as analysts factor in recent price target cuts tied to Q4 margin pressures, a softer 2026 EBITDA outlook, and concerns around payer mix, anesthesia costs, and a slower M&A contribution. Analyst Commentary Recent Street research around Surgery Partners has been active, with multiple firms revisiting their models after Q4 results and updated 2026 guidance.Recent updates
내러티브 업데이트 • Jun 30
SGRY: Q1 Execution And 2026 Outlook Will Support Margin Recovery
Analysts have revised their fair value estimate for Surgery Partners from $25.00 to about $23.49, citing updated assessments of discount rates, revenue growth, profit margins, and future P/E assumptions based on recent research. Analyst Commentary Recent Street research around Surgery Partners highlights a mix of adjustments to price targets, with some bullish analysts focusing on the company’s capacity to execute on its plans while reassessing risk and return assumptions.분석 기사 • Jun 19
Surgery Partners (SGRY) Stock Could Be 19% Undervalued As Growth And Debt Concerns Build
Recent commentary on Surgery Partners (SGRY) has focused on slowing sales volume growth, softer revenue growth expectations, and ongoing high debt levels. This combination appears to be affecting sentiment toward the stock. See our latest analysis for Surgery Partners. At a share price of $14.55, Surgery Partners has seen a 30 day share price return of 7.86% and a 90 day share price return of 23.31%. However, the 1 year total shareholder return is down 24.61%, pointing to some recent momentum...내러티브 업데이트 • Jun 15
SGRY: Reset Expectations And Steady Guidance Will Shape Future Multiple Potential
Analysts cut the fair value estimate for Surgery Partners stock by $4 to $14, reflecting updated assumptions around revenue growth, profit margins, the discount rate, and a lower future P/E multiple, despite recent mixed price target moves at Jefferies. Analyst Commentary Recent research shows mixed views on Surgery Partners, with some analysts adjusting price targets in both directions over a short period.내러티브 업데이트 • Jun 01
SGRY: Margin Repair And Payer Mix Reset Will Support 2026 EBITDA Recovery
The analyst-derived fair value estimate for Surgery Partners has shifted from about $18.80 to roughly $17.95, as analysts factor in recent price target cuts tied to Q4 margin pressures, a softer 2026 EBITDA outlook, and concerns around payer mix, anesthesia costs, and a slower M&A contribution. Analyst Commentary Recent Street research around Surgery Partners has been active, with multiple firms revisiting their models after Q4 results and updated 2026 guidance.내러티브 업데이트 • May 02
SGRY: Margin Pressures Will Ease As 2026 M&A Upside Reemerges
Narrative Update on Surgery Partners Analysts have trimmed the average price target for Surgery Partners by a few dollars into the mid to high teens, citing Q4 EBITDA and margin shortfalls, a weaker payer mix, anesthesia related cost pressures, softer 2026 guidance, and reduced expectations for M&A contribution. Analyst Commentary Price targets across the Street have been revised lower into a tighter band, generally in the mid to low US$20s and mid to high teens, following the Q4 miss and 2026 EBITDA guidance that came in below prior expectations.내러티브 업데이트 • Apr 18
SGRY: Margin Pressures Will Ease As M&A Optionality Reshapes 2026 Outlook
Analysts have reduced the average price target for Surgery Partners by roughly $8 to $10 per share to a range of about $14 to $24, citing Q4 EBITDA shortfalls, margin pressures from payer and insurance mix shifts, anesthesia related costs, and softer 2026 guidance that excludes potential M&A. Analyst Commentary Recent research shows that while price targets have moved lower across the Street, several bullish analysts still see upside potential for Surgery Partners relative to current trading levels.내러티브 업데이트 • Apr 04
SGRY: Margin Repair And Payer Mix Management Will Support A Constructive 2026 Reset
The analyst price target for Surgery Partners has been reduced from about $25.45 to about $18.80. Analysts cite weaker Q4 EBITDA, margin pressure from a tougher payer and insurance mix, anesthesia-related cost pressures, and more cautious 2026 guidance as key drivers of their updated views.내러티브 업데이트 • Mar 21
SGRY: Margin Reset And M&A Optionality Will Counter Anesthesia And Payer Mix Pressures
Narrative Update on Surgery Partners The analyst price target for Surgery Partners has moved lower by several dollars into a $14 to $24 range, as analysts factor in recent Q4 EBITDA shortfalls, weaker margins, anesthesia and payer mix headwinds, and management's 2026 guidance that sits below prior consensus and assumes limited M&A. Analyst Commentary Recent Street commentary on Surgery Partners centers on Q4 earnings that came in below expectations, margin pressure tied to anesthesia costs, and a less favorable payer mix.내러티브 업데이트 • Mar 06
SGRY: Margin Reset And M&A Optionality Are Expected To Ease Payer Mix Pressures
The analyst fair value estimate for Surgery Partners has been reduced from $33.00 to $25.00 as analysts factor in lower Q4 EBITDA, margin pressure related to payer mix and anesthesia costs, and softer 2026 guidance that assumes fewer deals than previously modeled. Analyst Commentary Street research has broadly reset expectations on Surgery Partners, with several firms lowering their price targets after Q4 results and the updated 2026 outlook.내러티브 업데이트 • Feb 20
SGRY: New Baylor Partnership Will Set Up Future Multiple Rebound Potential
Analysts have kept their $18.00 price target for Surgery Partners unchanged, citing consistent assumptions regarding revenue growth, profit margins, and future P/E as support for this view. What's in the News Surgery Partners agreed to a new partnership with Baylor Scott & White Health to jointly own The Physicians Centre Hospital, a 16 bed facility in Bryan, Texas, alongside physicians (Key Developments).내러티브 업데이트 • Feb 06
SGRY: Payer Mix Pressures Will Set Up Future Multiple Rebound Potential
Analysts have reduced their price target on Surgery Partners to US$18 from US$24, citing weaker earnings visibility from payer mix and volume pressures, a higher discount rate, more conservative revenue growth assumptions, and an adjustment to a lower future P/E multiple. Analyst Commentary Recent research updates on Surgery Partners point to a reset in expectations, with several firms cutting price targets across the board.내러티브 업데이트 • Jan 23
SGRY: Asset Divestitures And Deleveraging Are Expected To Reset Payer Mix Pressures
Narrative Update Analysts have reduced their price targets on Surgery Partners to a range of roughly US$18 to US$31, citing lower earnings visibility tied to payer mix and volume pressures, slower M&A activity, and updated guidance that still assumes a favorable backdrop for asset divestitures and ambulatory surgery center demand. Analyst Commentary Across recent research updates, analysts have generally reduced price targets for Surgery Partners into the US$18 to US$31 range while still highlighting several areas that they see as supportive for the equity story.내러티브 업데이트 • Jan 09
SGRY: Upcoming Divestitures And Deleveraging Will Support A Constructive 2025 Reset
Analysts have trimmed their price targets on Surgery Partners, resulting in a modest change in estimated fair value from about $25.73 to $25.45, as they factor in payer mix pressure, softer recent performance, slower M&A activity, and updated expectations for volumes and earnings visibility. Analyst Commentary Recent research paints a mixed picture for Surgery Partners, with price targets moving lower but opinions split on how temporary the current pressures might be.내러티브 업데이트 • Dec 25
SGRY: Upcoming Asset Divestitures Are Expected To Drive Material Balance Sheet Deleveraging
Analysts have trimmed their fair value estimate for Surgery Partners to $33 from $36. This reflects lower price targets across the Street as they factor in softer volume trends, payer mix headwinds, reduced earnings visibility and a slower M&A cadence, partially offset by confidence in long term ASC tailwinds and de-leveraging from asset divestitures.내러티브 업데이트 • Dec 11
SGRY: Upcoming Divestitures And Deleveraging Will Drive A Constructive Reset In 2025
Surgery Partners price target has been revised lower, with analysts trimming expectations by mid single digit dollars per share to reflect weaker than expected recent performance, payer mix and volume pressures, slower M&A activity, and reduced near term earnings visibility, even as they highlight supportive long term fundamentals and a still constructive outlook on asset divestitures and deleveraging. Analyst Commentary Analysts are broadly revising models to reflect weaker near term trends, yet most still frame the stock as a valuation reset rather than a change in the long term thesis.내러티브 업데이트 • Nov 27
SGRY: Upcoming Divestitures And Deleveraging Will Drive Recovery In 2025
Analysts have lowered their price target for Surgery Partners from approximately $27.91 to $25.73. They cite recent earnings misses, payer mix headwinds, and delayed acquisitions as primary factors for the revision.내러티브 업데이트 • Nov 12
SGRY: Asset Divestitures And Acquisition Pipeline Will Drive Recovery Ahead
The analyst price target for Surgery Partners has decreased from $31 to approximately $27.91. Analysts cite lowered guidance due to slowing volume and payer mix trends, a delay in acquisitions, and a more cautious outlook for near-term growth.Seeking Alpha • Sep 08
Surgery Partners: Deleveraging Needs To Be The Priority
Summary Surgery Partners now trades at fair value after multiple compression, with returns on capital still lagging and leverage elevated, justifying my Hold rating. Q2 results were decent, but cash flow conversion and ambitious H2 margin targets highlight execution risks and limited room for error. Business economics show SGRY is capital intensive, with ROIC below the cost of capital, so growth currently destroys value unless returns improve. To upgrade my stance, I need to see sustained high-teen margins, clear deleveraging, and a shift to higher organic growth over acquisitions. Read the full article on Seeking Alpha새로운 내러티브 • May 26
Ambulatory Surgery Trends And Aging Will Expand Market Reach
Growth is driven by rising surgical case volumes in lower-cost centers and expanded specialties, supported by demographic trends and strategic network expansion.Seeking Alpha • Jan 30
Surgery Partners: A Buyout Could Be Justifiable Around This Level
Summary Surgery Partners received a non-binding offer from Bain Capital to acquire the rest of the company for $25.75 per share, valuing it at $3.25 billion. In the past, the stock had been pricey, but this is no longer the case based on current pricing. In recent years, financial performance has been solid and improving, particularly when it comes to cash flows. The market is cautiously optimistic about the offer, suggesting potential for a higher bid, but significant upside is unlikely. Read the full article on Seeking Alpha분석 기사 • Dec 08
Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues Pushing Shares 28% Lower
The Surgery Partners, Inc. ( NASDAQ:SGRY ) share price has fared very poorly over the last month, falling by a...분석 기사 • Nov 11
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Oct 24
Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues
It's not a stretch to say that Surgery Partners, Inc.'s ( NASDAQ:SGRY ) price-to-sales (or "P/S") ratio of 1.4x right...분석 기사 • Oct 05
Surgery Partners (NASDAQ:SGRY) Has Some Way To Go To Become A Multi-Bagger
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...분석 기사 • Jul 25
Surgery Partners, Inc. (NASDAQ:SGRY) Soars 25% But It's A Story Of Risk Vs Reward
Surgery Partners, Inc. ( NASDAQ:SGRY ) shareholders would be excited to see that the share price has had a great month...분석 기사 • Jul 13
Here's Why Surgery Partners (NASDAQ:SGRY) Has A Meaningful Debt Burden
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...분석 기사 • Jun 21
Slowing Rates Of Return At Surgery Partners (NASDAQ:SGRY) Leave Little Room For Excitement
To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...분석 기사 • May 31
We Think Shareholders Are Less Likely To Approve A Pay Rise For Surgery Partners, Inc.'s (NASDAQ:SGRY) CEO For Now
Key Insights Surgery Partners will host its Annual General Meeting on 6th of June CEO J. Evans' total compensation...분석 기사 • Apr 24
Surgery Partners, Inc.'s (NASDAQ:SGRY) Share Price Matching Investor Opinion
There wouldn't be many who think Surgery Partners, Inc.'s ( NASDAQ:SGRY ) price-to-sales (or "P/S") ratio of 1.2x is...분석 기사 • Mar 18
Surgery Partners' (NASDAQ:SGRY) Returns Have Hit A Wall
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...분석 기사 • Feb 27
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Dec 19
The Price Is Right For Surgery Partners, Inc. (NASDAQ:SGRY)
There wouldn't be many who think Surgery Partners, Inc.'s ( NASDAQ:SGRY ) price-to-sales (or "P/S") ratio of 1.5x is...분석 기사 • Oct 26
Returns Are Gaining Momentum At Surgery Partners (NASDAQ:SGRY)
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...분석 기사 • Sep 17
Does Surgery Partners (NASDAQ:SGRY) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Aug 26
Are Investors Undervaluing Surgery Partners, Inc. (NASDAQ:SGRY) By 35%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Surgery Partners fair value estimate is US$52.34 Surgery...주주 수익률
| SGRY | US Healthcare | US 시장 | |
|---|---|---|---|
| 7D | 2.7% | 2.0% | 1.6% |
| 1Y | -22.8% | 28.7% | 18.6% |
수익률 대 산업: SGRY은 지난 1년 동안 28.7%의 수익을 기록한 US Healthcare 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: SGRY은 지난 1년 동안 18.6%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| SGRY volatility | |
|---|---|
| SGRY Average Weekly Movement | 4.9% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: SGRY는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: SGRY의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2004 | 16,000 | J. Evans | www.surgerypartners.com |
는 자회사와 함께 미국에서 수술 시설 및 보조 서비스 네트워크를 소유 및 운영하고 있습니다. 이 회사는 정형외과 및 통증 관리, 안과, 소화기내과, 일반외과 등 다양한 전문 분야에서 비응급 수술 절차를 제공하는 외래 수술 센터와 외과 병원을 제공합니다. 응급실, 의사 진료 및 진단 테스트와 같은 보조 서비스, 여러 전문의 진료, 응급 치료 시설, 마취 서비스 등을 제공합니다.
Surgery Partners, Inc. 기초 지표 요약
| SGRY 기초 통계 | |
|---|---|
| 시가총액 | US$2.23b |
| 순이익 (TTM) | -US$76.10m |
| 매출 (TTM) | US$3.34b |
0.7x
주가매출비율(P/S)-28.9x
주가수익비율(P/E)SGRY는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| SGRY 손익계산서 (TTM) | |
|---|---|
| 매출 | US$3.34b |
| 매출원가 | US$2.58b |
| 총이익 | US$763.30m |
| 기타 비용 | US$839.40m |
| 순이익 | -US$76.10m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -0.59 |
| 총이익률 | 22.83% |
| 순이익률 | -2.28% |
| 부채/자본 비율 | 80.4% |
SGRY의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/06 22:06 |
| 종가 | 2026/07/06 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Surgery Partners, Inc.는 21명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Steven Valiquette | Barclays |
| Sarah James | Barclays |
| Andrew Mok | Barclays |